In multiple myeloma (MM), IRF4 is a critical transcription factor whose activity and cellular growth effects can be deregulated by the loss of the inhibitory protein BCL7A, which normally limits its DNA binding activity 53. The gene discussed is IRF4; the disease is Miyoshi myopathy.